Corcept Therapeutics

Senior Director, Revenue and Cost Accounting

Redwood City, California, United States

Auto‑apply with AI Apply

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Healthcare, Biotechnology, PharmaceuticalsIndustries

Requirements

Candidates should possess a Bachelor’s degree in Accounting or a related field, along with a minimum of 10 years of progressive accounting experience, preferably within the biotechnology or pharmaceutical industry. Strong knowledge of US GAAP and SEC reporting requirements is essential, as is experience with NetSuite.

Responsibilities

The Senior Director, Revenue and Cost Accounting will oversee the end-to-end revenue close process, ensuring accuracy and compliance with GAAP, and will manage journal entries, accounts receivable reconciliations, and gross-to-net payments. They will also oversee inventory accounting, including manufacturing accruals and inventory reconciliation, and lead revenue-related workstreams for new product launches, while maintaining strategic partnerships with vendors and ensuring government pricing accuracy.

Skills

GAAP

NetSuite

Revenue Accounting

Cost Accounting

Government Pricing

NFAMP

AMP Verification

PHS Pricing

Team Management

Leadership

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Key Metrics

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free